Immix Biopharma posts positive safety data for soft tissue cancer candidate

Jan. 19, 2022 9:13 AM ETImmix Biopharma, Inc. (IMMX)By: Dulan Lokuwithana, SA News Editor
  • Immix Biopharma (NASDAQ:IMMX) is trading ~3.6% higher after announcing 100% completion of planned treatment cycles in an ongoing Phase 1b/2a clinical trial for IMX-110, its candidate for soft tissue sarcoma (STS).
  • Only 43-67% of patients, who received currently approved drugs for the condition, have completed planned treatment cycles historically, the company noted.
  • IMX-110 is currently under investigation as monotherapy for STS, a condition with an estimated $3B market opportunity that is projected to reach $6B by 2030. The FDA has granted the company the orphan drug designation for IMX-110 in STS.
  • “In this interim clinical trial update, we are thrilled to report that IMX-110 has been well tolerated,” CEO Ilya Rachman remarked.
  • Read more on promising data for IMX-110 from a mouse model with STS.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.